← Human Trials & Peer-Reviewed Studies
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy
Plain-language guide to PMID 15708700 (2005): randomized controlled trial study of BNP (Nesiritide) in 6 patients.
Key Facts
- PMID
- 15708700
- Journal
- Journal of the American College of Cardiology
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Lindahl B et al. (7 authors)
- DOI
- 10.1016/j.jacc.2004.10.057
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.
Long-term temporal changes of NT-proBNP levels and their relation to other factors have not been examined.
Who Took Part
According to the abstract, 6 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
The NT-proBNP was analyzed at randomization and at 48 h, after 6 weeks, 3 and 6 months in NSTEACS patients enrolled in the Fragmin and fast Revascularisation during InStability in Coronary artery disease (FRISC)-II trial.
The NT-proB-type natriuretic peptide was analyzed at least three time points in 1,216 patients.
How the Study Was Run
The design is described as randomized.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The timeline in the abstract includes 6 weeks.
What Was Measured
Long-term temporal changes of NT-proBNP levels and their relation to other factors have not been examined.
PubMed files the paper under topics including Acute Disease, Angina, Unstable, Dalteparin, Electrocardiography, Fibrinolytic Agents, Myocardial Infarction and Natriuretic Peptide, Brain.
What This Means in Plain Language
The paper is a randomized study of BNP (Nesiritide) in 6 patients over 6 weeks.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.